Company: Daiichi Sankyo
Job title: Chief Researcher
Kenji Iida has 25 years of pharmaceutical research experience at Daiichi Sankyo (DS) Co., Ltd. Where he is currently Chief Researcher of Oncology Research Laboratories. He has been working on DS-6157a, one of the projects in DXd-ADC pipeline in DS, since target discovery. Prior to this, he was working on target discovery and screening of small molecule inhibitors for the treatment of joint diseases and viral infections, among other early research projects. He graduated from Kyoto University and received his BS and MS in agricultural chemistry in 1992 and 1994.
DS-6157a, A GPR20 Targeting ADC for the Treatment of Gastrointestinal Stromal Tumor (GIST) 4:00 pm
GPR20 is an orphan GPCR, selectively and abundantly expressed in GIST DS-6157a is a DNA topoisomerase I inhibitor Exatecan-derivative based ADC, entering phase I trial in 2020 In preclinical studies, DS-6157a showed antitumor activity and preferable safety profilesRead more
day: Day Two